# Genome Compiler Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genome-compiler

- Industry: Software
- Headquarters: Los Altos, US
- Website: www.genomecompiler.com
- Total disclosed funding: $5.8M
- Latest round: Series A (Jun 1, 2015)
- Investors on record: 1

## About

Genome Compiler Corporation offers innovative technology solutions for genetic engineering, specializing in software applications that simplify the design and analysis of DNA sequences.Founded in 2011 and headquartered in Los Altos, US, Genome Compiler Corporation focuses on providing software for genetic engineering. The company has secured a total of USD 5.75 mn through 3 funding rounds, with the latest being a Series A round in April 2016. In that round, NFX was a notable investor. The company was acquired by Twist Bioscience in April 2016, though the financial terms of the deal were not disclosed.The company specializes in technology solutions for genetic engineering, offering software applications that enhance operational efficiency and streamline data management. Its products are utilized primarily by businesses in sectors like biotech and pharmaceuticals, addressing challenges in DNA sequencing and analysis. Genome Compiler Corporation serves markets in North America, Western Europe, and parts of Asia, catering to a diverse range of clients including large corporations and research institutions.The revenue model is structured around a subscription-based framework, allowing clients to access its software through various pricing tiers. This structure encourages long-term client relationships, typically through annual contracts that include support and maintenance services. The company engages in B2B transactions and direct-to-consumer sales depending on the specific product offerings, ensuring competitive pricing to attract a wide customer base while delivering robust service.Looking ahead, Genome Compiler Corporation plans to expand its product offerings with new software solutions designed for advanced genetic analysis by the end of 2018. The company is targeting expansion into markets in Asia and Europe, particularly focusing on biotech firms and research organizations. The funding from the Series A round will support these initiatives, enabling further research and development to enhance their product suite and reach new clients.

## Funding rounds

- Series A, Jun 1, 2015, $5.8M — NFX

## Investors

- NFX (https://capitalatlas.ai/funds/nfx) — Series A